KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Revenue (2016 - 2025)

NovoCure (NVCR) has disclosed Revenue for 12 consecutive years, with $174.4 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 8.11% to $174.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $655.4 million through Dec 2025, up 8.28% year-over-year, with the annual reading at $655.4 million for FY2025, 8.28% up from the prior year.
  • Revenue hit $174.4 million in Q4 2025 for NovoCure, up from $167.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $174.4 million in Q4 2025 to a low of $122.2 million in Q1 2023.
  • Historically, Revenue has averaged $142.1 million across 5 years, with a median of $136.1 million in 2021.
  • Biggest five-year swings in Revenue: surged 32.28% in 2021 and later decreased 11.17% in 2023.
  • Year by year, Revenue stood at $133.2 million in 2021, then dropped by 3.59% to $128.4 million in 2022, then grew by 4.17% to $133.8 million in 2023, then increased by 20.54% to $161.3 million in 2024, then rose by 8.11% to $174.4 million in 2025.
  • Business Quant data shows Revenue for NVCR at $174.4 million in Q4 2025, $167.2 million in Q3 2025, and $158.8 million in Q2 2025.